Report Detail
Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights, Forecast to 2025
- RnM2923661 |
- 12 February, 2019 |
- Global |
- 115 Pages |
- QYResearch |
- Pharma & Healthcare
The global Resistant Pseudomonas Aeruginosa Infections Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Resistant Pseudomonas Aeruginosa Infections Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Resistant Pseudomonas Aeruginosa Infections Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Resistant Pseudomonas Aeruginosa Infections Drugs in these regions.
This research report categorizes the global Resistant Pseudomonas Aeruginosa Infections Drugs market by top players/brands, region, type and end user. This report also studies the global Resistant Pseudomonas Aeruginosa Infections Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
ContraFect Corp
Inhibrx LP
Achaogen Inc
LegoChem Biosciences Inc
Melinta Therapeutics Inc
Novartis AG
AmpliPhi Biosciences Corp
Biolytics Pharma
Shionogi & Co Ltd
Market size by Product
Semi-Synthetic Penicillin
Cephalosporin
Lactam Drugs
Others
Market size by End User
Hospital
Clinic
Home Care
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Resistant Pseudomonas Aeruginosa Infections Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Resistant Pseudomonas Aeruginosa Infections Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Resistant Pseudomonas Aeruginosa Infections Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Resistant Pseudomonas Aeruginosa Infections Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Resistant Pseudomonas Aeruginosa Infections Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Resistant Pseudomonas Aeruginosa Infections Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by Product
- 1.4.2 Semi-Synthetic Penicillin
- 1.4.3 Cephalosporin
- 1.4.4 Lactam Drugs
- 1.4.5 Others
- 1.5 Market by End User
- 1.5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Clinic
- 1.5.4 Home Care
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size
- 2.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2014-2025
- 2.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2014-2025
- 2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Growth Rate by Regions
- 2.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Regions
- 2.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers
- 3.1.1 Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Manufacturers
- 3.1.2 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers
- 3.2.1 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Resistant Pseudomonas Aeruginosa Infections Drugs Price by Manufacturers
- 3.4 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Resistant Pseudomonas Aeruginosa Infections Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Resistant Pseudomonas Aeruginosa Infections Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Product
- 4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Product
- 4.3 Resistant Pseudomonas Aeruginosa Infections Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Breakdown Data by End User
6 North America
- 6.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs by Countries
- 6.1.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries
- 6.1.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs by Product
- 6.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs by End User
7 Europe
- 7.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs by Countries
- 7.1.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries
- 7.1.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs by Product
- 7.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs by Countries
- 8.1.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries
- 8.1.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs by Product
- 8.3 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs by End User
9 Central & South America
- 9.1 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs by Countries
- 9.1.1 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries
- 9.1.2 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs by Product
- 9.3 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs by Countries
- 10.1.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Countries
- 10.1.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs by Product
- 10.3 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs by End User
11 Company Profiles
- 11.1 ContraFect Corp
- 11.1.1 ContraFect Corp Company Details
- 11.1.2 Company Business Overview
- 11.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.1.5 ContraFect Corp Recent Development
- 11.2 Inhibrx LP
- 11.2.1 Inhibrx LP Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.2.5 Inhibrx LP Recent Development
- 11.3 Achaogen Inc
- 11.3.1 Achaogen Inc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.3.5 Achaogen Inc Recent Development
- 11.4 LegoChem Biosciences Inc
- 11.4.1 LegoChem Biosciences Inc Company Details
- 11.4.2 Company Business Overview
- 11.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.4.5 LegoChem Biosciences Inc Recent Development
- 11.5 Melinta Therapeutics Inc
- 11.5.1 Melinta Therapeutics Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.5.5 Melinta Therapeutics Inc Recent Development
- 11.6 Novartis AG
- 11.6.1 Novartis AG Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.6.5 Novartis AG Recent Development
- 11.7 AmpliPhi Biosciences Corp
- 11.7.1 AmpliPhi Biosciences Corp Company Details
- 11.7.2 Company Business Overview
- 11.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.7.5 AmpliPhi Biosciences Corp Recent Development
- 11.8 Biolytics Pharma
- 11.8.1 Biolytics Pharma Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.8.5 Biolytics Pharma Recent Development
- 11.9 Shionogi & Co Ltd
- 11.9.1 Shionogi & Co Ltd Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Products Offered
- 11.9.5 Shionogi & Co Ltd Recent Development
12 Future Forecast
- 12.1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by Regions
- 12.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by Product
- 12.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Forecast by Product 2019-2025
- 12.3 Resistant Pseudomonas Aeruginosa Infections Drugs Market Forecast by End User
- 12.4 North America Resistant Pseudomonas Aeruginosa Infections Drugs Forecast
- 12.5 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Forecast
- 12.6 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Forecast
- 12.7 Central & South America Resistant Pseudomonas Aeruginosa Infections Drugs Forecast
- 12.8 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Resistant Pseudomonas Aeruginosa Infections Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Resistant Pseudomonas Aeruginosa Infections Drugs . Industry analysis & Market Report on Resistant Pseudomonas Aeruginosa Infections Drugs is a syndicated market report, published as Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Resistant Pseudomonas Aeruginosa Infections Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
